8 Apr 2024 • In acute MI patients who underwent early coronary angiography and had a preserved left ventricular ejection fraction (≥50%), long-term beta-blocker therapy showed no significant benefit.

• A large study published in the New England Journal of Medicine found no significant difference in the primary composite endpoint of death from any cause or new MI between the beta-blocker and non-beta-blocker groups (7.9% vs. 8.3%; HR 0.96).
• Safety endpoints also demonstrated comparable rates of adverse events, suggesting no clear benefit from beta-blocker therapy in this patient population.

Source: NEJM | Read full story